A Phase 2 interventional study of Ticagrelor and Clopidogrel in Stable Coronary Artery Disease, sponsored by AstraZeneca. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-04.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.
Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 32nd largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 3rd registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Shiraz University of Medical Sciences · Sites in Iran, Islamic Republic of
Ages 20–80
University of Florida · Sites in United States
Ages 18+
St. Antonius Hospital · Sites in Netherlands
Ages 18+
Campus Bio-Medico University · Sites in Italy
Ages 18+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 18 · Phase 4 46
First in 2006; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is below the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 80 across the 78 interventional studies. Of the 59 that completed or were terminated, 26 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 78 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
25 studies in Coronary Artery Disease by AstraZeneca: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 11 (46%) have results posted.
Among the 25 studies in Coronary Artery Disease by AstraZeneca, this one is the 11th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2008, is one of 5 in phase 2, and was the 6th registered.
AstraZeneca’s Coronary Artery Disease studies by the year they started, since 2001.
1 of the studies testing ticagrelor in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06228456University of FloridaEffects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 78 studies testing ticagrelor in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 25 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated the effect of Ticagrelor on inhibition of platelet aggregation compared with clopidogrel in patients previously identified as non-responsive to clopidogrel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aspirin + Ticagrelor
Drug: Ticagrelor · Drug: Aspirin
Aspirin + Clopidogrel
Drug: Clopidogrel · Drug: Aspirin
Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
Also known as: Plavix
Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.)
The primary definition of response to treatment is IPA \>10% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: Day 14 and Day 28, 4 Hrs Post Dose.
Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.
The secondary definition of response to treatment is IPA \>50% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: Day 14, and day 28, 4 hours post dose
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 15
IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.
Time frame: Day 15, 4 hrs post switching
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 28
IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.
Time frame: 4 hrs post first dose on day 28
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 15
IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.
Time frame: Day 15, 4 hrs post switching
Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 28
IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.
Time frame: 4 hrs post first dose on day 28
| Milestone | Clopidogrel Non-responders - Clopidogrel to Ticagrelor | Clopidogrel Non-responders - Ticagrelor to Clopidogrel | Clopidogrel Responders - Clopidogrel to Clopidogrel | Clopidogrel Responders - Clopidogrel to Ticagrelor | Clopidogrel Responders - Ticagrelor to Clopidogrel | Clopidogrel Responders - Ticagrelor to Ticagrelor |
|---|---|---|---|---|---|---|
| Started | 20 | 21 | 13 | 16 | 14 | 14 |
| Completed | 17 | 17 | 13 | 15 | 13 | 13 |
| Not completed | 3 | 4 | 0 | 1 | 1 | 1 |
| Withdrew: Adverse event | 2 | 3 | 0 | 0 | 0 | 1 |
| Withdrew: Developement of discontinuation criteria | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Severe non-compliance to protocol | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 1 | 0 | 0 |
The primary definition of response to treatment is IPA \>10% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percent of Participants | Non-responder: Ticagrelor | Non-responder: Clopidogrel |
|---|---|---|
| Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.) | 100 | 93.8 |
The secondary definition of response to treatment is IPA \>50% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percent of participants | Non-responder: Ticagrelor | Non-responder: Clopidogrel |
|---|---|---|
| Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop. | 81.3 | 25.0 |
IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.
| Percent | Responder: Ticagrelor | Responder: Clopidogrel |
|---|---|---|
| Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 15 | 66.7 (49.7 to 83.7) | 65.3 (46.5 to 84.2) |
IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.
| Percent | Responder: Ticagrelor | Responder: Clopidogrel |
|---|---|---|
| Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 28 | 91.0 (77.1 to 104.9) | 61.2 (46.4 to 76.0) |
IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.
| Percent | Responder: Ticagrelor | Responder: Clopidogrel |
|---|---|---|
| Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 15 | 95.0 (87.7 to 102.4) | 48.5 (40.8 to 56.2) |
IPA(%)=(PAb-PAt)/PAb\*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered.
| Percent | Responder: Ticagrelor | Responder: Clopidogrel |
|---|---|---|
| Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 28 | 77.4 (67.0 to 87.8) | 60.8 (49.9 to 71.7) |
Collected over Switching Period - first 24 hrs (Day 15), patients switched study medication (from clop. to ticag. or vice versa). Non-Switching Period - Day 1-14 and Day 16-28.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clopidogrel Non-Responders/Non-Switching Period: Ticagrelor | — | 2/39 (5.1%) | 13/39 (33.3%) |
| Clopidogrel Non-Responders/Non-Switching Period: Clopidogrel | — | 0/38 (0%) | 13/39 (33.3%) |
| Clop. Non-Responders/Switching Period:Ticagrelor-Clopidogrel | — | 0/18 (0%) | 1/18 (5.6%) |
| Clop. Non-Responders/Switching Period: Clopidogrel-Ticagrelor | — | 0/18 (0%) | 4/18 (22.2%) |
| Clop. Responders/Non-Switching Period: Ticagrelor | — | 2/44 (4.5%) | 19/44 (43.2%) |
| Clop. Responders/Non-Switching Period: Clopidogrel | — | 0/42 (0%) | 14/42 (33.3%) |
| Clop. Responders/Switching Period: Ticagrelor-Clopidogrel | — | 0/13 (0%) | 2/13 (15.4%) |
| Clop. Responders/Switching Period: Clopidogrel-Ticagrelor | — | 0/16 (0%) | 1/16 (6.3%) |
| Event | Clopidogrel Non-Responders/Non-Switching Period: Ticagrelor | Clopidogrel Non-Responders/Non-Switching Period: Clopidogrel | Clop. Non-Responders/Switching Period:Ticagrelor-Clopidogrel | Clop. Non-Responders/Switching Period: Clopidogrel-Ticagrelor | Clop. Responders/Non-Switching Period: Ticagrelor | Clop. Responders/Non-Switching Period: Clopidogrel | Clop. Responders/Switching Period: Ticagrelor-Clopidogrel | Clop. Responders/Switching Period: Clopidogrel-Ticagrelor |
|---|---|---|---|---|---|---|---|---|
| Myocardial InfarctionCardiac disorders | 1/39 | 0/38 | 0/18 | 0/18 | 0/44 | 0/42 | 0/13 | 0/16 |
| HypotensionVascular disorders | 1/39 | 0/38 | 0/18 | 0/18 | 0/44 | 0/42 | 0/13 | 0/16 |
| Atrial FibrillationCardiac disorders | 0/39 | 0/38 | 0/18 | 0/18 | 1/44 | 0/42 | 0/13 | 0/16 |
| BradycardiaCardiac disorders | 0/39 | 0/38 | 0/18 | 0/18 | 1/44 | 0/42 | 0/13 | 0/16 |
| Ventricular ExtrasystolesCardiac disorders | 0/39 | 0/38 | 0/18 | 0/18 | 1/44 | 0/42 | 0/13 | 0/16 |
| Event | Clopidogrel Non-Responders/Non-Switching Period: Ticagrelor | Clopidogrel Non-Responders/Non-Switching Period: Clopidogrel | Clop. Non-Responders/Switching Period:Ticagrelor-Clopidogrel | Clop. Non-Responders/Switching Period: Clopidogrel-Ticagrelor | Clop. Responders/Non-Switching Period: Ticagrelor | Clop. Responders/Non-Switching Period: Clopidogrel | Clop. Responders/Switching Period: Ticagrelor-Clopidogrel | Clop. Responders/Switching Period: Clopidogrel-Ticagrelor |
|---|---|---|---|---|---|---|---|---|
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 7/39 | 3/38 | 1/18 | 2/18 | 6/44 | 0/42 | 0/13 | 0/16 |
| DIZZINESSNervous system disorders | 1/39 | 3/38 | 0/18 | 2/18 | 1/44 | 1/42 | 0/13 | 0/16 |
| DYSPEPSIAGastrointestinal disorders | 0/39 | 0/38 | 0/18 | 0/18 | 1/44 | 4/42 | 0/13 | 0/16 |
| NAUSEAGastrointestinal disorders | 0/39 | 1/38 | 0/18 | 0/18 | 0/44 | 4/42 | 0/13 | 0/16 |
| FATIGUEGeneral disorders | 0/39 | 1/38 | 0/18 | 0/18 | 1/44 | 2/42 | 1/13 | 0/16 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/39 | 0/38 | 0/18 | 0/18 | 0/44 | 1/42 | 1/13 | 0/16 |
| MYALGIAMusculoskeletal and connective tissue disorders | 0/39 | 1/38 | 0/18 | 0/18 | 0/44 | 0/42 | 1/13 | 0/16 |
| INCREASED TENDENCY TO BRUISESkin and subcutaneous tissue disorders | 3/39 | 1/38 | 0/18 | 0/18 | 2/44 | 2/42 | 0/13 | 1/16 |
| CONTUSIONInjury, poisoning and procedural complications | 0/39 | 0/38 | 0/18 | 0/18 | 3/44 | 0/42 | 0/13 | 0/16 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 0/39 | 0/38 | 0/18 | 0/18 | 3/44 | 0/42 | 0/13 | 0/16 |
| Age Continuous(year) | Clopidogrel Non-responders - Clopidogrel to Ticagrelor | Clopidogrel Non-responders - Ticagrelor to Clopidogrel | Clopidogrel Responders - Clopidogrel to Clopidogrel | Clopidogrel Responders - Clopidogrel to Ticagrelor | Clopidogrel Responders - Ticagrelor to Clopidogrel | Clopidogrel Responders - Ticagrelor to Ticagrelor | Total |
|---|---|---|---|---|---|---|---|
| Mean | 67.25 ± 8.12 | 64.57 ± 6.31 | 65.46 ± 8.68 | 64.56 ± 8.56 | 63.21 ± 9.23 | 61.57 ± 8.22 | 64.8 ± 7.95 |
| Sex: Female, Male(Participants) | Clopidogrel Non-responders - Clopidogrel to Ticagrelor | Clopidogrel Non-responders - Ticagrelor to Clopidogrel | Clopidogrel Responders - Clopidogrel to Clopidogrel | Clopidogrel Responders - Clopidogrel to Ticagrelor | Clopidogrel Responders - Ticagrelor to Clopidogrel | Clopidogrel Responders - Ticagrelor to Ticagrelor | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 8 | 3 | 2 | 3 | 1 | 22 |
| Male | 15 | 13 | 10 | 14 | 11 | 13 | 76 |
The record gives a start of May 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor